SUPRIYA

Supriya Lifescience Share Price

₹728.70 +35.45 (5.11%)

20 Jan, 2025 16:42

SIP TrendupStart SIP in SUPRIYA

Start SIP

Performance

  • Low
  • ₹698
  • High
  • ₹733
  • 52 Week Low
  • ₹289
  • 52 Week High
  • ₹835
  • Open Price₹713
  • Previous Close₹693
  • Volume245,333

Investment Returns

  • Over 1 Month -4.7%
  • Over 3 Month + 31.27%
  • Over 6 Month + 88.56%
  • Over 1 Year + 139.19%
SIP Lightning

Smart Investing Starts Here Start SIP with Supriya Lifescience for Steady Growth!

Invest Now

Supriya Lifescience Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 37.2
  • PEG Ratio
  • 0.6
  • Market Cap Cr
  • 5,865
  • P/B Ratio
  • 6.5
  • Average True Range
  • 35.49
  • EPS
  • 19.57
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -7.17
  • RSI
  • 46.29
  • MFI
  • 63.49

Supriya Lifescience Financials

Supriya Lifescience Technicals

EMA & SMA

Current Price
₹728.70
+ 35.45 (5.11%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹706.81
  • 50 Day
  • ₹699.65
  • 100 Day
  • ₹648.27
  • 200 Day
  • ₹559.96

Resistance and Support

683.1 Pivot Speed
  • R3 760.10
  • R2 731.05
  • R1 712.15
  • S1 664.20
  • S2 635.15
  • S3 616.25

What's your outlook on Supriya Lifescience?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Supriya Lifescience is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) with over 38 APIs across various therapeutic segments. It exports to 86 countries, supplying high-quality APIs for pharmaceuticals, nutraceuticals, and personal care industries.

Supriya Lifescience has an operating revenue of Rs. 624.98 Cr. on a trailing 12-month basis. An annual revenue growth of 24% is outstanding, Pre-tax margin of 29% is great, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 31% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 83 which is a GOOD score indicating consistency in earnings, a RS Rating of 90 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 42 indicates it belongs to a fair industry group of Medical-Supplies and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Supriya Lifescience Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-01-24 Quarterly Results
2024-10-28 Quarterly Results
2024-08-10 Quarterly Results
2024-05-28 Audited Results & Final Dividend
2024-02-07 Quarterly Results

Supriya Lifescience F&O

Supriya Lifescience Shareholding Pattern

68.3%
0.67%
2.49%
6.52%
16.27%
5.75%

About Supriya Lifescience

  • NSE Symbol
  • SUPRIYA
  • BSE Symbol
  • 543434
  • ISIN
  • INE07RO01027

Similar Stocks to Supriya Lifescience

Supriya Lifescience FAQs

Supriya Lifescience share price is ₹728 As on 20 January, 2025 | 16:28

The Market Cap of Supriya Lifescience is ₹5864.8 Cr As on 20 January, 2025 | 16:28

The P/E ratio of Supriya Lifescience is 37.2 As on 20 January, 2025 | 16:28

The PB ratio of Supriya Lifescience is 6.5 As on 20 January, 2025 | 16:28

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23